Rallybio (RLYB) Competitors $0.32 +0.02 (+5.23%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. MRSN, OTLK, ANEB, FBRX, VNRX, NBRV, MURA, CNTB, ITRM, and ATRAShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Mersana Therapeutics (MRSN), Outlook Therapeutics (OTLK), Anebulo Pharmaceuticals (ANEB), Forte Biosciences (FBRX), VolitionRx (VNRX), Nabriva Therapeutics (NBRV), Mural Oncology (MURA), Connect Biopharma (CNTB), Iterum Therapeutics (ITRM), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Mersana Therapeutics Outlook Therapeutics Anebulo Pharmaceuticals Forte Biosciences VolitionRx Nabriva Therapeutics Mural Oncology Connect Biopharma Iterum Therapeutics Atara Biotherapeutics Rallybio (NASDAQ:RLYB) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts rate RLYB or MRSN? Rallybio presently has a consensus price target of $10.00, indicating a potential upside of 3,025.00%. Mersana Therapeutics has a consensus price target of $4.00, indicating a potential upside of 824.00%. Given Rallybio's higher probable upside, research analysts clearly believe Rallybio is more favorable than Mersana Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Mersana Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in RLYB or MRSN? Mersana Therapeutics received 208 more outperform votes than Rallybio when rated by MarketBeat users. However, 73.33% of users gave Rallybio an outperform vote while only 66.14% of users gave Mersana Therapeutics an outperform vote. CompanyUnderperformOutperformRallybioOutperform Votes4473.33% Underperform Votes1626.67% Mersana TherapeuticsOutperform Votes25266.14% Underperform Votes12933.86% Does the media prefer RLYB or MRSN? In the previous week, Rallybio had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 2 mentions for Rallybio and 1 mentions for Mersana Therapeutics. Rallybio's average media sentiment score of 0.93 equaled Mersana Therapeutics'average media sentiment score. Company Overall Sentiment Rallybio Positive Mersana Therapeutics Positive Which has more volatility and risk, RLYB or MRSN? Rallybio has a beta of -1.35, indicating that its share price is 235% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Is RLYB or MRSN more profitable? Rallybio has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -214.20%. Rallybio's return on equity of -77.39% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RallybioN/A -77.39% -69.33% Mersana Therapeutics -214.20%-401.37%-38.61% Which has stronger earnings & valuation, RLYB or MRSN? Rallybio has higher earnings, but lower revenue than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$636K20.94-$74.56M-$1.35-0.24Mersana Therapeutics$40.50M1.33-$171.67M-$0.56-0.77 Do institutionals & insiders hold more shares of RLYB or MRSN? 90.3% of Rallybio shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 8.7% of Rallybio shares are held by insiders. Comparatively, 11.8% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryMersana Therapeutics beats Rallybio on 10 of the 18 factors compared between the two stocks. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.65M$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.207.4422.4418.48Price / Sales20.94242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book0.116.516.774.25Net Income-$74.56M$143.21M$3.22B$248.23M7 Day Performance7.74%1.98%1.49%0.89%1 Month Performance-47.54%6.89%4.00%3.53%1 Year Performance-83.16%-2.52%16.21%5.08% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio2.3776 of 5 stars$0.32+5.2%$10.00+3,025.0%-83.3%$12.65M$636,000.00-0.2040Gap DownMRSNMersana Therapeutics3.8795 of 5 stars$0.38+5.5%$4.00+942.2%-86.3%$47.83M$40.50M-0.63150Upcoming EarningsGap DownOTLKOutlook Therapeutics1.8339 of 5 stars$1.48-3.3%$10.20+589.2%-82.4%$47.39MN/A-0.2020Positive NewsANEBAnebulo Pharmaceuticals2.0105 of 5 stars$1.15+0.9%$8.00+595.7%-58.3%$47.25MN/A-4.114Short Interest ↑News CoverageFBRXForte Biosciences3.5563 of 5 stars$7.12+6.1%$32.50+356.5%+24,865.8%$46.86MN/A-0.445Options VolumePositive NewsGap UpVNRXVolitionRx1.8098 of 5 stars$0.46-4.9%$3.33+619.9%-46.7%$46.65M$1.23M-1.2980Analyst ForecastGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070Analyst ForecastMURAMural Oncology3.1913 of 5 stars$2.61+0.4%$13.00+398.1%-28.9%$44.97MN/A-0.29119CNTBConnect Biopharma2.5814 of 5 stars$0.81+3.7%$8.00+887.7%-40.9%$44.83M$24.12M0.00110ITRMIterum Therapeutics2.5534 of 5 stars$1.26flat$5.00+296.8%-26.8%$43.57MN/A-0.9610Short Interest ↓News CoveragePositive NewsGap UpATRAAtara Biotherapeutics4.0384 of 5 stars$7.42+1.4%$17.75+139.2%-53.7%$43.47M$128.94M-0.29330Positive News Related Companies and Tools Related Companies Mersana Therapeutics Alternatives Outlook Therapeutics Alternatives Anebulo Pharmaceuticals Alternatives Forte Biosciences Alternatives VolitionRx Alternatives Nabriva Therapeutics Alternatives Mural Oncology Alternatives Connect Biopharma Alternatives Iterum Therapeutics Alternatives Atara Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLYB Stock Free RLYB Stock Alerts